McDermott Advised Innate Pharma S.A. on Entering into an Exclusive Licensing Agreement with Takeda

McDermott Will & Emery advised Innate Pharma S.A., a clinical-stage biotechnology company developing cancer immunotherapies, in entering into an exclusive licensing agreement with Takeda.

Innate Pharma grants Takeda exclusive worldwide rights to research and development of Antibody Drug Conjugates (ADC), generated from a panel of antibodies against an undisclosed target developed by Innate, primarily in celiac disease.
Takeda will be responsible for the development, manufacturing and commercialization of potential products developed using the licensed antibodies.

The McDermott team that advised Innate Pharma S.A. was composed of :

• Emmanuelle Trombe, partner, Katya Ascher, counsel (Life Sciences)
• Côme de Saint Vincent, counsel (Tax)